Curemark Issued Patent for the Diagnosis of Parkinson's Disease

RYE, N.Y., Sept. 8, 2011 /PRNewswire/ -- Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it was issued Patent 8,012,710: Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders.  The patent covers Curemark's biomarker as applied to diagnosing an individual with Parkinson's disease, as well as determining if an individual has a likelihood to develop Parkinson's disease.

Parkinson's disease is a degenerative neurological disorder that affects one million individuals in the United States and more than five million worldwide.  Curemark's patent also includes the diagnosis of specific other dysautonomic conditions including Familial Dysautonomia (FD), Diabetic autonomic failure, and Orthostatic Intolerance.

"Curemark's technology, especially as applied to Parkinson's, represents one of the first novel patented biomarkers for Parkinson's disease," states Matthew Heil, PhD, Sr. Vice President of Research and Development at Curemark. "This biomarker, which indicates enzyme deficiencies, can be used to diagnose the disease and also can be utilized as an early screening tool to identify those who may have the propensity to develop Parkinson's disease."

Dr. Joan Fallon, CEO of Curemark states, "This patent represents a further advancement of our breakthrough platform technology.  We hope that the diagnosis of Parkinson's and other dysautonomias through the use of our biomarker could potentially help not only with early diagnosis, but also with the development of treatments to mitigate the symptoms of Parkinson's disease and other dysautonomias."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.